NCT07534033 Phase II Clinical Study of Probiotic LR607 in Patients With Non-Small Cell Lung Cancer
| NCT ID | NCT07534033 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Zhujiang Hospital |
| Condition | NSCLC Diagnosed by Histology or Cytology |
| Study Type | INTERVENTIONAL |
| Enrollment | 46 participants |
| Start Date | 2025-12-06 |
| Primary Completion | 2026-12-23 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 46 participants in total. It began in 2025-12-06 with a primary completion date of 2026-12-23.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to understand whether Lactobacillus rhamnosus LR607 can enhance neoadjuvant chemoimmunotherapy for adult patients with non-small cell lung cancer. It will also evaluate the safety of LR607. The main questions it aims to answer include: Can LR607 improve the major pathological response of neoadjuvant chemoimmunotherapy? What is the relationship between LR607 combined with neoadjuvant chemoimmunotherapy and treatment-related adverse reactions? What changes occur in the gut microbiota composition at the species level and gut metabolites of subjects after LR607 treatment? Participants will: Take LR607 daily for 3 months Visit the hospital for check-ups and examinations every month Record their pathological response, tumor recurrence, and treatment-related adverse reactions
Eligibility Criteria
Inclusion Criteria: 1. Histologically confirmed newly diagnosed patients 2. ECOG performance status 0-1 3. Age ≥18 years 4. Measurable lesions (RECIST v1.1) 5. Organ function meeting the requirements for chemotherapy and immunotherapy. Exclusion Criteria: 1. Including active autoimmune diseases 2. Recent use of immunosuppressants 3. Interstitial lung disease 4. Presence of other malignancies 5. History of immunotherapy 6. Active infection 7. Pregnancy or drug allergies
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07534033 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying NSCLC Diagnosed by Histology or Cytology. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07534033 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07534033 currently recruiting?
Yes, NCT07534033 is actively recruiting participants. Contact the research team at 1098353704@qq.com for enrollment information.
Where is the NCT07534033 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT07534033 clinical trial?
NCT07534033 is sponsored by Zhujiang Hospital. The trial plans to enroll 46 participants.